SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that it will release financial results for the three and twelve months ended December 31, 2007 after market close on Thursday, March 13, 2008.
Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, and David Ramsay, Vice President and Chief Financial Officer, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Friday, March 14, 2008, to provide a pipeline update.
Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's web site at http://www.halozyme.com. A replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation code 38622372.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
products based on the extracellular matrix for the drug delivery, oncology
and dermatology markets. The company's portfolio of products and product
candidates is based on intellectual property covering the family of human
enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a
novel drug delivery platform designed to increase the absorption and
dispersion of biologics. Its key partnerships are with Roche to apply
Enhanze Technology to Roche's biological therapeutic compounds for up to 13
targets and with Baxter to apply Enhanze Technology to Baxter's biological
therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has
received FDA approval for two products: Cumulase(R), for use in in-vitro
fertilization, and HYLENEX, for use as an adjuvant to increase the
absorption and dispersion of other injected drugs and fluids. HYLENEX is
partnered with Baxter International Inc. The Company also has a number of
different enzymes in its portfolio that are targeting significant areas of
David A. Ramsay
Chief Financial Officer
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved